EMMESSAR BIOTECH & NUTRITION LTD.

Emmessar Biotech & Nutrition Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 01, 2026, and will continue until 48 hours after the financial results for the quarter ending June 30, 2026, are made public. This measure is in compliance with SEBI's Prohibition of Insider Trading Regulations, 2015, aimed at preventing potential misuse of unpublished price-sensitive information.

Emmessar Biotech & Nutrition Ltd's Board of Directors approved the audited standalone financial results for the year ended March 31, 2026, following a review by the Audit Committee. The board meeting, held on May 12, 2026, also included a declaration on the audit report with an unmodified opinion from V. Nagarajan & Co., Chartered Accountants.

Emmessar Biotech & Nutrition Ltd's Board of Directors approved the audited standalone financial results for the year ended March 31, 2026, following a review by the Audit Committee. The board meeting, held on May 12, 2026, also included a declaration confirming an unmodified opinion from the statutory auditors, V. Nagarajan & Co.

Emmessar Biotech & Nutrition Ltd has scheduled a Board of Directors meeting on May 12, 2026, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2026. The trading window for dealing in the company's equity shares will remain closed until May 14, 2026.

Emmessar Biotech & Nutrition Ltd has announced that pursuant to clause 4 of the Schedule B of SEBI Prohibition of Insider Trading Regulations, 2015, the trading window for dealing in the securities of the company will be closed from April 01, 2026 till the end of 48 hours after the financial results for the financial year and quarter ending March 31, 2026, become generally available information. This move is to ensure compliance with the SEBI (PIT) regulations.

Emmessar Biotech & Nutrition Ltd, a company based in Maharashtra, India, has announced its unaudited financial results for the quarter ended 31st December 2025. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11th February 2026. The company operates in two segments: Healthcare and Rent on Leasehold Land. No investor complaints were received during the quarter. The results are in compliance with the Indian Accounting Standards and the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company will continue to monitor the impact of the recently notified Labour Codes.

Emmessar Biotech & Nutrition Ltd. has reported its unaudited financial results for the quarter ended 31st December 2025. The results have been reviewed by the Audit Committee and approved by the Board of Directors. The company operates two segments: Healthcare and Rent on Leasehold Land. No investors' complaints were received during the quarter. The results are in compliance with the Indian Accounting Standards and the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company will continue to monitor the impact of the recently notified Labour Codes.

Emmessar Biotech & Nutrition Ltd has announced that its Board of Directors will meet on February 11, 2026, in Mumbai to consider and approve the unaudited Financial Results for the quarter ended December 31, 2025. In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015, and the SEBI (Prohibition of Insider Trading), Regulations, 2015, as amended from time to time, the trading window for equity shares of the company will remain closed until February 13, 2026.

Emmessar Biotech & Nutrition Ltd has announced that the trading window for dealing in the securities of the company will be closed with effect from January 01, 2026 till the end of 48 hours after the financial results of the company for the quarter ending December 31, 2025, become generally available information. This decision is in accordance with clause 4 of the Schedule B of SEBI Prohibition of Insider Trading Regulations, 2015.

Emmessar Biotech & Nutrition Ltd, a company based in Mumbai, has reported its unaudited financial results for the quarter ended 30th September 2025. The company's total revenue for the quarter stands at ₹ 1,32,00,000, with a net profit of ₹ 6,80,000. The results have been reviewed by the Audit Committee and approved by the Board of Directors. The company operates in two segments: Healthcare and Nutrition, both on leasehold land.